TheraCell Patents and Trademarks

The following TheraCell products and services are protected by patents in the United States and in other jurisdictions of the world. Additionally, TheraCell has licensed some of its technology to various parties in the US and Australia who are also selling products covered by TheraCell patents. This webpage is provided to satisfy the virtual patent marking provisions of various jurisdictions including the virtual patent marking provisions of the America Invents Act and to provide notice under 35 U.S.C. §287(a). The following list of products and services may not be all inclusive, and other products and services not listed here may be protected by one or more patents in the United States and elsewhere. Additional patents may be pending in the United States and elsewhere.

One or more implants, instruments, and/or techniques associated with the product names below may be covered by one or more of the United States Patents indicated:

 

Product

TheraFuze DBF® FiberForm™
TheraFuze DBF® FiberForm +™
TheraFuze DBF® Fiber Anchor™
TheraFuze DBF® Fiber Bullets™
TheraFuze DBF® Fiber Wrap™
TheraFuze DBF® FiberForm Syringe™
TheraFuze DBF® FiberForm + Syringe™
TheraFuze DBF® Fiber Boat™

US Patent(s)

US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912

 

AlloSource is a licensee of the following patents (US 9,486,557, US 9,572,912) and produces products using TheraCell's demineralized bone fiber (DBF®) technology. They also distribute products as well as providing products to other distributors (NuVasive). Australian Biotechnologies Inc.is a licensee of AUS 2014253753 and produces products using TheraCell's DBF® technology. One or more implants, instruments, and/or techniques associated with the product names below may be covered by one or more of the United States Patents indicated:

 

AlloSource Product

AlloFuse® Cortical Fibers
AlloFuse® Fiber Boat

US Patent(s)

US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912

 
 

NuVasive Product

Propel® DBM Fibers
Propel® Fiber Boat

US Patent(s)

US 9,486,557, US 9,572,912
US 9,486,557, US 9,572,912

 

Patent Portfolio – Demineralized Bone Fiber Based Products
In addition to the patents cited above Theracell has worked diligently to file a number of patent applications to cover enhancements to the base DBF technology and specific procedure specific products.

Patent Portfolio – Enhanced Cancellous Sponge
AlloSource is a licensee of the following patents (US 9,636,436) and produces products using TheraCell's enhanced cancellous technology. Australian Biotechnologies Inc.is a licensee of AUS 2014235352 and produces products using TheraCell's enhanced cancellous technology. One or more implants, instruments, and/or techniques associated with the product names below may be covered by one or more of the United States Patents indicated:

 

Product

AlloFlex® Plus

US Patent(s)

US 9,636,436

 

Patent Portfolio - Oxygenation
TheraCell has a number of approaches to oxygenating implants and these are covered by a number of patents that have been issued, with other patents pending. Issued patents are:
US 8,859,007, US 9,308,295, AUS 2014205119, US 9,687,589

TheraFuze DBF® FiberForm™, TheraFuze DBF® FiberForm +™, TheraFuze DBF® Fiber Anchor™, TheraFuze DBF® Fiber Bullets™, TheraFuze DBF® Fiber Wrap™, TheraFuze DBF® FiberForm Syringe™, TheraFuze DBF® FiberForm + Syringe™, TheraFuze DBF® Fiber Boat™, Fiberlok™, and Bone Textile™ are trademarks of TheraCell, Inc.

AlloFuse® and AlloFlex® are registered trademarks of AlloSource and Propel® is a registered trademark of NuVasive, Inc.